Context Therapeutics Inc.
CNTX
$1.09
$0.032.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.04% | -6.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.73% | 76.49% | |||
| Operating Income | -8.73% | -76.49% | |||
| Income Before Tax | -9.81% | -92.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.81% | -92.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.81% | -92.85% | |||
| EBIT | -8.73% | -76.49% | |||
| EBITDA | -8.74% | -76.55% | |||
| EPS Basic | -9.82% | -92.72% | |||
| Normalized Basic EPS | -9.66% | -92.69% | |||
| EPS Diluted | -9.82% | -92.72% | |||
| Normalized Diluted EPS | -9.66% | -92.69% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||